Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eugene R. Baizman is active.

Publication


Featured researches published by Eugene R. Baizman.


Microbiology | 2000

Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase.

Eugene R. Baizman; Arthur A. Branstrom; Clifford B. Longley; Nigel M. Allanson; T. Michael J. Sofia; David Gange; Robert C. Goldman

Moenomycin is a natural product glycolipid that inhibits the growth of a broad spectrum of Gram-positive bacteria. In Escherichia coli, moenomycin inhibits peptidoglycan synthesis at the transglycosylation stage, causes accumulation of cell-wall intermediates, and leads to lysis and cell death. However, unlike Esc. coli, where 5-6 log units of killing are observed, 0-2 log units of killing occurred when Gram-positive bacteria were treated with similar multiples of the MIC. In addition, bulk peptidoglycan synthesis in intact Gram-positive cells was resistant to the effects of moenomycin. In contrast, synthetic disaccharides based on the moenomycin disaccharide core structure were identified that were bactericidal to Gram-positive bacteria, inhibited cell-wall synthesis in intact cells, and were active on both sensitive and vancomycin-resistant enterococci. These disaccharide analogues do not inhibit the formation of N:-acetylglucosamine-ss-1, 4-MurNAc-pentapeptide-pyrophosphoryl-undecaprenol (lipid II), but do inhibit the polymerization of lipid II into peptidoglycan in Esc. coli. In addition, cell growth was required for bactericidal activity. The data indicate that synthetic disaccharide analogues of moenomycin inhibit cell-wall synthesis at the transglycosylation stage, and that their activity on Gram-positive bacteria differs from moenomycin due to differential targeting of the transglycosylation process. Inhibition of the transglycosylation process represents a promising approach to the design of new antibacterial agents active on drug-resistant bacteria.


Bioorganic & Medicinal Chemistry Letters | 1993

Peptide azoles: A new class of biologically-active dipeptide mmetics.

Thomas D. Gordon; Philip E. Hansen; Barry A. Morgan; Jasbir Singh; Eugene R. Baizman; Susan Jean Ward

Abstract Appropriately substituted thiazoles, imidazoles and oxazoles have been designed to be useful mimetics of dipeptide moieties. These “peptide azoles” have been shown to be potent antagonists of substances P as measured by isolated tissue assays such as the isolated guinea-pig ileum. A novel, chiral synthesis of these peptide azoles from aminoacids has been developed.


Bioorganic & Medicinal Chemistry Letters | 2000

Differential antibacterial activity of moenomycin analogues on gram-positive bacteria

Robert C. Goldman; Eugene R. Baizman; Arthur A. Branstrom; Clifford B. Longley

The moenomycin trisaccharide degradation product and synthetic disaccharide analogues based on the disaccharide core were bactericidal to gram-positive bacteria, inhibited lipid II polymerization, and inhibited cell wall synthesis in Enterococcus faecalis. Truncating moenomycin to the trisaccharide, and building upon the core disaccharide have both led to molecules possessing properties not shared with their respective parent structures.


Bioorganic & Medicinal Chemistry Letters | 2000

Synthesis and biological evaluation of analogues of bacterial Lipid I

Domingos J. Silva; Caryn Lang Bowe; Arthur A. Branstrom; Eugene R. Baizman; Michael J. Sofia

Bacterial Lipid I analogues containing different anomeric groups at the muramic acid moiety were synthesized and screened in MurG enzyme assays run in the presence and absence of cell wall membranes. The results obtained in this study help elucidate the role of the lipid diphosphate in the recognition of Lipid I by MurG.


Journal of Medicinal Chemistry | 1985

3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants.

Denis M. Bailey; Philip E. Hansen; Allan G. Hlavac; Eugene R. Baizman; Jack Pearl; Albert DeFelice; Martin E. Feigenson


Journal of Medicinal Chemistry | 1994

5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase.

Roland E. Dolle; Joseph A. Dunn; Mark A. Bobko; Baldev Singh; Joan E. Kuster; Eugene R. Baizman; Alex L. Harris; David G. Sawutz; Deborah Miller; Su Wang; Connie R. Faltynek; Wen Xie; Jay Sarup; D. Christopher Bode; Edward D. Pagani; Paul J. Silver


Journal of Medicinal Chemistry | 1999

Discovery of Novel Disaccharide Antibacterial Agents Using a Combinatorial Library Approach

Michael J. Sofia; Nigel M. Allanson; Nicole T. Hatzenbuhler; Rakesh K. Jain; Ramesh Kakarla; Natan Kogan; Rui Liang; Dashan Liu; Domingos J. Silva; Huiming Wang; David Gange; Jan Anderson; Anna Chen; Feng Chi; Richard Dulina; Buwen Huang; Muthoni G. Kamau; Chunguang Wang; Eugene R. Baizman; Arthur A. Branstrom; Neil Bristol; Robert Goldman; Kiho Han; Clifford B. Longley; Sunita Midha; Helena R. Axelrod


Fems Microbiology Letters | 2000

Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding

Robert C. Goldman; Eugene R. Baizman; Clifford B. Longley; Arthur A. Branstrom


Analytical Biochemistry | 2000

Assay for identification of inhibitors for bacterial MraY translocase or MurG transferase.

Arthur A. Branstrom; Sunita Midha; Clifford B. Longley; Kiho Han; Eugene R. Baizman; Helena R. Axelrod


Journal of Medicinal Chemistry | 2002

Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria.

Svetlana S. Printsevskaya; Andrey Y. Pavlov; Evgenia N. Olsufyeva; Elena P. Mirchink; Elena B. Isakova; Marina I. Reznikova; Robert C. Goldman; Arthur A. Branstrom; Eugene R. Baizman; Clifford B. Longley; Ferenc Sztaricskai; Gyula Batta; M. N. Preobrazhenskaya

Collaboration


Dive into the Eugene R. Baizman's collaboration.

Top Co-Authors

Avatar

Arthur A. Branstrom

Walter Reed Army Institute of Research

View shared research outputs
Top Co-Authors

Avatar

Robert C. Goldman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jasbir Singh

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Philip E. Hansen

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Susan Jean Ward

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Albert DeFelice

Rensselaer Polytechnic Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge